Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert


Search Title by author or title

Epithelium-on photorefractive intrastromal cross-linking (PiXL) with supplemental oxygen for low hyperopic treatment in untreated Asian eyes

Poster Details

First Author: W.Lim SINGAPORE

Co Author(s):    J. Theng   M. Puah   C. Chua   F. Gasper   F. Khoo        

Abstract Details


To report the 6 months results of low hyperopic correction with epithelium-on PiXL with supplementary oxygen


Eagle Eye Centre, Singapore


PiXL procedure was conducted on patients with normal (non-ectatic) corneas for low hyperopic treatment. The PiXL treatment were designed to deliver a 9mm annulus ring of 1mm thickness (for hyperopic treatment) of UVA light with supplemental oxygen at a rate of 2mL/minute. Clinical evaluation included safety (BCVA, ECC, anterior ocular health) and efficacy (UCVA, manifest refraction, keratometric parameters) checks. 4 dominant eyes were treated for distance vision while 8 non-dominant eyes were treated for near vision. Questionnaires were conducted to analyse the patient’s subjective experience with the procedure during their 1st and 6th months post procedure review.


12 ametropic eyes (median +0.94DS; range -0.25 to +1.50D) of 8 subjects (mean age 48 years old; range 38 to 55) were assessed. 1-month data revealed a median refractive change of -0.44D (range -1.00D to -0.13D) and median Kmean steepening of 0.40D (range -0.2 to 0.8D). Median UDVA improved from 0.13 logMAR (range 0.04 to 0.20) pre-PiXL to -0.03 logMAR (range -0.04 to 0.04) at 1 month while median UNVA improved from N12 (range N6 to N18) pre-PiXL to N5 at 1 month.


Early results of hyperopic PiXL with oxygen are encouraging especially with noticeable improvement in near vision. However, longer-term data to assess the sustainability of the treatment and larger studies are still required

Financial Disclosure:

research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to Poster listing